XML 42 R31.htm IDEA: XBRL DOCUMENT
v3.25.0.1

REVENUE (Tables) | 3 Months Ended
--- | ---
Jan. 31, 2025
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended Jan 31,
| 2025 |  | 2024
| Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total |  | Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 312 |  |  | $ | 261 |  |  | $ | 96 |  |  | $ | 669 |  |  | $ | 283 |  |  | $ | 253 |  |  | $ | 94 |  |  | $ | 630 |
Europe | 190 |  |  | 188 |  |  | 85 |  |  | 463 |  |  | 184 |  |  | 185 |  |  | 89 |  |  | 458 |
Asia Pacific | 145 |  |  | 247 |  |  | 157 |  |  | 549 |  |  | 153 |  |  | 248 |  |  | 169 |  |  | 570 |
Total | $ | 647 |  |  | $ | 696 |  |  | $ | 338 |  |  | $ | 1,681 |  |  | $ | 620 |  |  | $ | 686 |  |  | $ | 352 |  |  | $ | 1,658 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
|  |  | Three Months Ended
|  |  | Jan 31,
|  |  |  |  | 2025 |  | 2024
|  |  |  | (in millions)
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical |  |  |  |  | $ | 585 |  |  | $ | 565 |
Diagnostics and Clinical |  |  |  |  | 240 |  |  | 228 |
Academic and Government |  |  |  |  | 137 |  |  | 150 |
Chemicals and Advanced Materials |  |  |  |  | 379 |  |  | 392 |
Food |  |  |  |  | 168 |  |  | 157 |
Environmental and Forensics |  |  |  |  | 172 |  |  | 166 |
Total |  |  |  |  | $ | 1,681 |  |  | $ | 1,658 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation |  |  |  |  | $ | 625 |  |  | $ | 630 |
Non-instrumentation and other |  |  |  |  | 1,056 |  |  | 1,028 |
Total |  |  |  |  | $ | 1,681 |  |  | $ | 1,658 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the changes in the balances during the three months ended January 31, 2025:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2024 |  | $ | 701 |
Net revenue deferred in the period |  | 312 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (230) |
Change in deferrals from customer cash advances, net of revenue recognized |  | 14 |
Currency translation and other adjustments |  | (15) |
Ending balance as of January 31, 2025 |  | $ | 782 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration